| Literature DB >> 27307436 |
Daniel J Munson1, Colt A Egelston2, Kami E Chiotti3, Zuly E Parra1, Tullia C Bruno1, Brandon L Moore1, Taizo A Nakano1, Diana L Simons2, Grecia Jimenez2, John H Yim4, Dmitri V Rozanov3, Michael T Falta5, Andrew P Fontenot6, Paul R Reynolds7, Sonia M Leach8, Virginia F Borges9, John W Kappler10, Paul T Spellman3, Peter P Lee2, Jill E Slansky11.
Abstract
Infiltration of T cells in breast tumors correlates with improved survival of patients with breast cancer, despite relatively few mutations in these tumors. To determine if T-cell specificity can be harnessed to augment immunotherapies of breast cancer, we sought to identify the alpha-beta paired T-cell receptors (TCRs) of tumor-infiltrating lymphocytes shared between multiple patients. Because TCRs function as heterodimeric proteins, we used an emulsion-based RT-PCR assay to link and amplify TCR pairs. Using this assay on engineered T-cell hybridomas, we observed ∼85% accurate pairing fidelity, although TCR recovery frequency varied. When we applied this technique to patient samples, we found that for any given TCR pair, the dominant alpha- or beta-binding partner comprised ∼90% of the total binding partners. Analysis of TCR sequences from primary tumors showed about fourfold more overlap in tumor-involved relative to tumor-free sentinel lymph nodes. Additionally, comparison of sequences from both tumors of a patient with bilateral breast cancer showed 10% overlap. Finally, we identified a panel of unique TCRs shared between patients' tumors and peripheral blood that were not found in the peripheral blood of controls. These TCRs encoded a range of V, J, and complementarity determining region 3 (CDR3) sequences on the alpha-chain, and displayed restricted V-beta use. The nucleotides encoding these shared TCR CDR3s varied, suggesting immune selection of this response. Harnessing these T cells may provide practical strategies to improve the shared antigen-specific response to breast cancer.Entities:
Keywords: T-cell receptors; T-cell repertoire profiling; breast cancer; emulsion RT-PCR; high-throughput sequencing
Mesh:
Substances:
Year: 2016 PMID: 27307436 PMCID: PMC4961128 DOI: 10.1073/pnas.1606994113
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205